Loading
Life sciences · Journal article
Drug Development Research · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Cyclin‐dependent kinases (CDKs) represent highly attractive anticancer targets and several inhibitors have been approved for cancer therapy. However, drug resistance and dose‐dependent toxicity have limited clinical application. Therefore, discovering new CDKs inhibitors featuring novel scaffolds and high selectivity for disease treatment and target research remains to attract significant interest from both academics and industry. Recently, thiazole has emerged as a privileged heterocyclic scaffold for design and synthesis of antitumor drugs targeting CDKs. Currently, although there are no FDA‐approved thiazole‐based CDKs inhibitors, this review systematically summarizes the evolution of inhibitors from early hits to clinical‐stage candidates including GFH009, SNS‐032, and JSH‐150, with particular emphasis on structure‐based drug design strategies. Furthermore, we highlight the challenges and future prospects in development of thiazole derivatives targeting CDKs, with particular emphasis on discovery of next‐generation, highly selective inhibitors.